iPSC-derived CAR-NK cells: Off-the-shelf cellular therapy for systemic sclerosis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40780183.
- Also identified by DOI 10.1016/j.cell.2025.07.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor (CAR) T cell therapy has opened new possibilities for patients with refractory autoimmune diseases such as systemic sclerosis, but personalized manufacturing and treatment-related toxicities limit its broader use. In this preview, we discuss the first clinical application of an off-the-shelf, iPSC-derived CAR-NK cell product in systemic sclerosis as reported by Wang et al. in this issue of Cell.
Medical subject headings
- Scleroderma, Systemic
- Induced Pluripotent Stem Cells
- Receptors, Chimeric Antigen
- Killer Cells, Natural
- Immunotherapy, Adoptive
- Cell- and Tissue-Based Therapy